Regulation - ACADIA Pharmaceuticals

Filter

Current filters:

ACADIA Pharmaceuticals

Popular Filters

FDA Breakthrough designation for ACADIA’s Nuplazid for Parkinson’s disease psychosis

FDA Breakthrough designation for ACADIA’s Nuplazid for Parkinson’s disease psychosis

03-09-2014

US biotech firm ACADIA Pharmaceuticals says that the US Food and Drug Administration has granted Breakthrough…

ACADIA PharmaceuticalsBiotechnologyNeurologicalNuplazidpimavanserinRegulationUSA

FDA backs NDA filing for ACADIA's Parkinson's candidate pimavanserin

11-04-2013

US biotech firm ACADIA Pharmaceuticals (Nasdaq: ACAD) saw its shares leap 42.8% to $7.97 in pre-market…

ACADIA PharmaceuticalsBiotechnologyNeurologicalNorth AmericapimavanserinRegulation

Back to top